Core Viewpoint - iBio, Inc. has announced a private placement financing expected to generate approximately $26 million in gross proceeds to advance its preclinical programs and extend its cash runway into 2028 [1][3]. Group 1: Financing Details - The private placement financing is led by Frazier Life Sciences and includes participation from existing healthcare-focused institutional investors [2]. - iBio is selling 11,061,738 shares of common stock at a purchase price of $2.35 per share, with the offering expected to close around January 13, 2026 [4]. - The financing will provide funds to support the development of preclinical cardiometabolic programs, including IBIO-610 and IBIO-600, and other pipeline assets [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to advance key development milestones in preclinical programs and to fund working capital requirements [3]. - The financing is expected to extend iBio's cash runway into calendar 2028, allowing for continued development of its biopharmaceutical pipeline [3]. Group 3: Company Overview - iBio, Inc. is a biotech company utilizing AI and advanced computational biology to develop biopharmaceuticals for various diseases, including cardiometabolic diseases and cancer [7]. - The company aims to transform drug discovery and accelerate development timelines through innovative drug discovery platforms [7].